Abstract:Poria cocos (PC) is a medicinal herb frequently used in weight-loss clinical trials, however the mechanisms by which its compounds target orexigenic receptors including the neuropeptide Y1 receptor (Y1R) remain largely unknown. This study aimed to screen PC compounds for favourable pharmacokinetics profiles and examine their molecular mechanisms targeting Y1R. Forty-three PC compounds were systematically sought from pharmacological databases and docked with Y1R (PDB: 5ZBQ). By comparing the relative binding affinities, pharmacokinetics and toxicity profiles, we hypothesised that compounds designated PC1 3,4-Dihydroxybenzoic acid, PC8 Vanillic acid, PC40 1-(alpha-L-Ribofuranosyl)uracil, could be potential antagonists as they contact major residues Asn283 and Asp287, similar to various potent Y1R antagonists. In addition, PC21 Poricoic acid B, PC22 Poricoic acid G and PC43 16alpha,25-Dihydroxy-24-methylene-3,4-secolanosta-4(28),7,9(11)-triene-3,21-dioic acid, contacting Asn299, Asp104 and Asp200 proximal to the extracellular surface could also interfere with agonist binding by stabilising the extracellular loop (ECL) 2 of Y1R in a closed position. Owing to their selective interaction with Phe302, an important residue in binding of selective Y1R antagonists, PC12 beta-Amyrin acetate, PC26 3-Epidehydrotumulosic acid and PC27 Cerevisterol were proposed as putative antagonists. Following the consensus approach, PC12 beta-Amyrin acetate, PC26 3-Epidehydrotumulosic acid and PC27 Cerevisterol were identified as candidate compounds due to their high affinities (-12.2, -11.0 and -10.8 kcal, respectively), high drug-likeness and low toxicity profiles. Trajectory analyses and energy contributions of PC12-Y1R complex further confirmed their structural stability and favourable binding free energies, highlighting the feasibility and possible development of PC12 beta-Amyrin acetate as a future Y1R inhibitor.

Discovery of small molecule agonists targeting neuropeptide Y4 receptor using homology modeling and virtual screening

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Structure-Activity Relationship Study of the High-Affinity Neuropeptide Y4 Receptor Positive Allosteric Modulator VU0506013

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Poria cocos compounds targeting neuropeptide Y1 receptor (Y1R) for weight management: A computational ligand- and structure-based study with molecular dynamics simulations identified beta-amyrin acetate as a putative Y1R inhibitor

Structural basis for ligand recognition of the neuropeptide Y Y2 receptor

Structural basis of ligand binding modes at the neuropeptide Y Y1 receptor

Molecular Modeling of the 3D Structure of 5-HT(1A)R: Discovery of Novel 5-HT(1A)R Agonists Via Dynamic Pharmacophore-Based Virtual Screening.

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

Discovery of Novel Allosteric Modulators Targeting an Extra-Helical Binding Site of GLP-1R Using Structure- and Ligand-Based Virtual Screening

Elucidating the Binding Mechanism of LPA Species and Analogs in an LPA4 Receptor Homology Model

Discover Natural Compounds As Potential Phosphodiesterase-4B Inhibitors Via Computational Approaches

Discovery of novel FFA4 (GPR120) receptor agonists with β-arrestin2-biased characteristics

Setmelanotide optimization through fragment-growing, molecular docking in-silico method targeting MC4 receptor

Homology modelling of CB1 receptor and selection of potential inhibitor against Obesity

Computational modeling toward understanding agonist binding on dopamine 3.

Discovery of Novel and Selective GPR17 Antagonists as Pharmacological Tools for Developing New Therapeutic Strategies in Diabetes and Obesity

Lipolysis and Apoptosis of Adipocytes Induced by Neuropeptide Y—Y5 Receptor Antisense Oligodeoxynucleotides in Obese Rats

Structural basis of peptidomimetic agonism revealed by small-molecule GLP-1R agonists Boc5 and WB4-24

From Hit to Lead: Structure-based Discovery of Naphthalene-1-sulfonamide Derivatives As Potent and Selective Inhibitors of Fatty Acid Binding Protein 4.

Discovery of novel nonpeptide small-molecule NRP1 antagonists: Virtual screening, molecular simulation and structural modification